StoneX Group’s Rein Therapeutics RNTX Stock Holding History

StoneX Group’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.84K	Buy	+11,783	New	+$9.7K	﹤0.01%	1862

Other funds holding RNTX

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $798M AUM 22.92% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $755M AUM 21.42% 1-Year Est. Return

Americana Partners Houston, Texas $4.67B AUM 26.97% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return

Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return

Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return

Chicago Partners Investment Group Chicago, Illinois $5.45B AUM 19.52% 1-Year Est. Return

Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return

Cane Capital Partners Saint Francisville, Louisiana $269M AUM 28.65% 1-Year Est. Return

StoneX Group's RNTX Position: Q3 2026 in Review

StoneX Group opened a new position in Rein Therapeutics (RNTX) in Q3 2026: 11,783 shares worth $8.84K. The stake represents ﹤0.01% of the portfolio and ranks #1862 among its holdings.

17 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.

StoneX Group held 11,783 shares of Rein Therapeutics worth $8.84K as of Q3 2026.
Rein Therapeutics was a new StoneX Group position in Q3 2026.
Rein Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1862 holding.
17 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.